🇺🇸 AMGN — Amgen Inc.

Salud Mantener
← Volver

Precio actual

460,28 USD

Máx. histórico

478,48

1 días

Split 2:1 del 22/11/1999

Caída desde máximo

-3,80%

Rango 52 semanas

312,39 – 483,99

Variación hoy

-3,80%

Cierre anterior

478,48

Rango de hoy

459,65 – 483,99

Volumen hoy

4.073.505

Peor caída histórica

-78,03%

17/06/1983 → 19/11/1984

Recuperado en 487 días

Volatilidad anualizada ⓘ

37,46%

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
26,68 (puede no estar actualizado)
Dividend yield
2,11% (puede no estar actualizado)
Precio objetivo analistas
404,32 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 1 día
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,16%
Fecha de pago Importe por participación
21/08/2026 2,5200 USD
15/05/2026 2,5200 USD
13/02/2026 2,5200 USD
21/11/2025 2,3800 USD
22/08/2025 2,3800 USD
16/05/2025 2,3800 USD
14/02/2025 2,3800 USD
18/11/2024 2,2500 USD
16/08/2024 2,2500 USD
16/05/2024 2,2500 USD
15/02/2024 2,2500 USD
16/11/2023 2,1300 USD
17/08/2023 2,1300 USD
17/05/2023 2,1300 USD
14/02/2023 2,1300 USD
Splits Registrados en el histórico de precios
Fecha Ratio
22/11/1999 2:1
01/03/1999 2:1
16/08/1995 2:1
11/09/1991 3:1
13/08/1990 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/05/2018 171,35 174,58 170,62 173,80 +0,85% 2,31% 2.494.200
15/05/2018 174,81 175,31 171,10 172,34 -2,06% 2,41% 4.491.700
14/05/2018 174,10 177,80 173,04 175,96 +1,19% 2,73% 3.370.600
11/05/2018 170,38 174,35 170,03 173,89 +1,83% 2,54% 3.740.500
10/05/2018 170,26 171,49 169,36 170,77 +0,67% 1,25% 2.947.100
09/05/2018 168,70 170,53 167,09 169,64 +0,68% 2,04% 2.861.400
08/05/2018 168,81 170,50 167,50 168,49 +0,26% 1,78% 3.937.700
07/05/2018 168,58 169,93 167,50 168,06 +0,05% 1,44% 3.175.800
04/05/2018 165,96 169,50 165,22 167,98 +0,96% 2,58% 3.430.000
03/05/2018 169,28 170,34 166,05 166,39 -1,79% 2,53% 4.152.900
02/05/2018 169,30 171,07 168,30 169,43 +0,09% 1,64% 4.085.700
01/05/2018 172,15 173,99 167,98 169,28 -2,98% 3,49% 4.799.400
30/04/2018 177,91 178,74 174,35 174,48 -1,68% 2,47% 3.608.700
27/04/2018 174,92 177,92 174,86 177,46 +1,19% 1,75% 2.424.800
26/04/2018 175,42 176,68 171,79 175,37 +0,31% 2,79% 3.682.400
25/04/2018 173,66 175,44 170,34 174,83 +1,68% 2,94% 4.693.800
24/04/2018 175,55 175,76 170,53 171,94 -1,56% 2,98% 4.389.400
23/04/2018 171,62 176,97 171,25 174,66 +1,81% 3,33% 3.568.700
20/04/2018 173,10 173,47 170,57 171,56 -0,79% 1,68% 2.958.600
19/04/2018 174,47 175,40 171,79 172,93 -1,24% 2,07% 2.269.400
18/04/2018 174,61 176,16 174,44 175,11 +0,13% 0,99% 2.205.600
17/04/2018 173,00 175,63 171,58 174,88 +2,04% 2,34% 3.283.900
16/04/2018 172,75 173,13 171,07 171,38 -0,06% 1,19% 2.656.400
13/04/2018 172,11 172,43 170,79 171,48 +0,27% 0,95% 2.656.400
12/04/2018 172,68 174,11 170,96 171,02 -0,81% 1,82% 3.471.400
11/04/2018 171,80 174,07 171,60 172,41 -0,42% 1,44% 2.575.900
10/04/2018 170,89 173,88 170,11 173,13 +2,07% 2,21% 2.872.300
09/04/2018 169,20 172,95 167,99 169,62 +0,88% 2,93% 3.856.800
06/04/2018 170,86 171,72 166,20 168,14 -2,24% 3,23% 3.747.800
05/04/2018 174,00 174,43 170,99 172,00 -0,88% 1,98% 2.766.600